Hikma Pharmaceuticals Public annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Capital Expenditures (CapEx) Growth & History (HIK)
Hikma Pharmaceuticals Public's capital expenditures (capex) was $197.0M for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $197.0M | $32.0M | +19.39% |
| 2024 | 2024-12-31 | $165.0M | −$4.0M | −2.37% |
| 2023 | 2023-12-31 | $169.0M | $31.0M | +22.46% |
| 2022 | 2022-12-31 | $138.0M | −$7.0M | −4.83% |
| 2021 | 2021-12-31 | $145.0M | −$27.0M | −15.70% |
| 2020 | 2020-12-31 | $172.0M | — | — |
Hikma Pharmaceuticals Public capital expenditures (capex) trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's capital expenditures (capex) increased from $172.0M to $197.0M, a change of $25.0M.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company official filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...